Literature DB >> 9492568

[A case of microscopic polyangitis accompanied by hearing loss as the initial sign of the disease].

Y Koseki1, A Suwa, T Nojima, K Ishiyama, A Nakajima, M Tanabe, T Yamada, M Goto, T Yasui, S Inada.   

Abstract

Here we report a case of microscopic polyangitis (MPA) with anti-neutrophil cytoplasmic antibodies against myeloperoxidase (MPO-ANCA) accompanied by perceptive dominant hearing loss as the initial sign of the disease. A 52-year-old woman was admitted to Tokyo Metropolitan Ohtsuka Hospital in April 1996 because of bilateral progressive hearing loss. On admission, she had presented bilateral perceptive hearing loss, fever, myalgia, and weight loss. Laboratory data showed accelerated erythrocyte sedimentation rate, proteinuria, microscopic hematuria, leukocytosis, hypoproteinemia, and elevated creatinine level. Serum level of MPO-ANCA was elevated. Chest X-ray and computed tomography showed mild pleural effusion and interstitial shadow in bilateral lung fields. The biopsy findings detected that focal glomerulonephritis, and necrotizing angitis of small artery in kidney. The diagnosis of MPA was made with clinical course, laboratory findings, radiographic findings, and biopsy finding. Treatment was initiated with 45 mg of prednisolone, followed by marked improvement of hearing loss and decreased titer of serum MPO-ANCA. There are only seven reports showing hearing loss as the initial sign of the disease occurred in polyarteritis nodosa and MPA. The present case suggests the possibility that hearing loss may be the symptom of MPO-ANCA associated vasculitis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9492568

Source DB:  PubMed          Journal:  Ryumachi        ISSN: 0300-9157


  1 in total

1.  The occurrence of sensorineural hearing loss in a patient with myeloperoxidase-anti-neutrophil cytoplasmic antibody-related microscopic polyangiitis.

Authors:  Toshiro Sugimoto; Masayoshi Sakaguchi; Naoko Deji; Takashi Uzu; Yoshihiko Nishio; Atsunori Kashiwagi
Journal:  Rheumatol Int       Date:  2007-03       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.